Core Insights - The U.S. marijuana industry is rapidly expanding with more states legalizing cannabis for medical and adult use, creating investment opportunities in leading marijuana stocks [1] - The top three marijuana stocks to watch in March 2026 are Trulieve Cannabis Corp. (TCNNF), Green Thumb Industries Inc. (GTBIF), and Curaleaf Holdings Inc. (CURLF), each showcasing unique strengths within the cannabis ecosystem [1][10] Trulieve Cannabis Corp. (TCNNF) - Trulieve is a major vertically integrated cannabis operator with over 150 dispensaries across high-demand states like Florida, California, and Pennsylvania [2] - The company has shown resilience in financial performance, with revenue growth and improved gross margins, while net income returned to profitability for consecutive quarters [4][6] - Trulieve's diversified model attracts investors focused on scale and brand penetration, supported by proprietary product technologies and strategic partnerships [2][4] Green Thumb Industries Inc. (GTBIF) - Green Thumb is a leading cannabis consumer packaged goods company, focusing on branded products and proprietary formulations distributed through over 20 state markets [6] - The latest financial results indicate stabilized revenue growth, particularly from branded product segments, with improved gross margins and positive EBITDA [7] - The company emphasizes innovation and strategic partnerships, enhancing its brand recognition and operational stability [6][7] Curaleaf Holdings Inc. (CURLF) - Curaleaf operates over 200 dispensaries in major cannabis markets and combines retail operations with cultivation and ancillary business segments [8] - Recent financial reports show continued revenue growth driven by product demand and improved operating efficiency, with a focus on high-growth product categories [9] - The company's diversified revenue mix and technology-enabled solutions position it as a resilient player in the cannabis sector [8][9]

Cronos Group (NasdaqGM:CRON) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnna Shlimak - CFOHarrison Aaron - Senior Director of Investor Relations and Corporate DevelopmentMike Gorenstein - Chairman, President, and CEORyan Neal - Equity Research AssociateConference Call ParticipantsBill Kirk - Managing Director and Senior Research AnalystKendrick Tai - Equity Research Analyst of Cannabis and Consumer GrowthPablo Zuanic - Founder, Managing Partner, and Equity Research Analyst of Ca ...

Core Insights - The Canadian cannabis sector is evolving with renewed investor interest, particularly in companies with U.S. exposure as regulatory discussions in the U.S. gain momentum [1][2][5] - Canadian cannabis companies are focusing on international revenue and operational discipline due to slowed growth in the domestic market [2][3] - Strategic partnerships and brand licensing are seen as alternative paths for growth amid challenges like oversupply and U.S. federal prohibition [4][5] Industry Overview - The Canadian recreational cannabis market is mature, but growth has decelerated compared to previous years, prompting companies to seek international opportunities [2] - Global cannabis reform is progressing, with countries like Germany expanding medical programs, which may benefit Canadian producers with international infrastructure [3] Company Profiles Tilray Brands Inc. (TLRY) - Tilray is a major Canadian cannabis producer with operations in Canada, Europe, Latin America, and the U.S., offering a diverse product portfolio [6][9] - The company has a strong U.S. presence through beverage alcohol brands and strategic partnerships, although it does not own THC dispensaries [7][9] - Recent quarterly revenue exceeded $200 million, showing modest year-over-year growth, with international sales contributing significantly [10] - Despite a net loss, the company has narrowed its losses and improved gross margins through operational efficiencies [11] Canopy Growth Corporation (CGC) - Canopy Growth is a well-known cannabis company producing a variety of products, including dried flower and beverages, with a broad brand portfolio [12][15] - The company has strategic arrangements for U.S. exposure but does not operate THC dispensaries [13][15] - Canopy has undergone restructuring to reduce costs and divest non-core assets, aiming for improved financial consistency [16][18] - Recent revenue trends have been mixed, but cost controls have helped reduce operating losses [17][18] Cronos Group Inc. (CRON) - Cronos focuses on branding and product innovation, operating in Canada, Israel, and select international markets [19][22] - The company relies on wholesale distribution and partnerships rather than a large dispensary network, with limited U.S. retail exposure [20][22] - Financially, Cronos has shown gradual improvement, with recent revenue growth driven by international demand, particularly from Israeli medical sales [23][24] - The company maintains a strong cash position, providing flexibility for future expansion, although overall revenue is smaller compared to competitors [24][25]

Core Viewpoint - Cannabis stocks have underperformed over the past five years, but recent positive regulatory changes in the U.S. may present long-term growth opportunities if the marijuana market expands significantly [1] Group 1: Canopy Growth - Canopy Growth is a leading player in the Canadian cannabis market with a diverse product portfolio, including dried cannabis flower, vapes, and edibles, and has a presence in multiple countries, including the U.S. [2] - Following President Trump's executive order to classify cannabis as a Schedule III substance, Canopy Growth may have expansion opportunities in the U.S. [3] - In Q3 2026, Canopy Growth reported net revenue of $54.62 million, a slight decrease of 0.3% year-over-year, but improved its net loss per share to $0.13 from $0.81 in the previous year [3] - If Canopy Growth can capitalize on U.S. opportunities and continue to reduce losses, it could yield strong returns [4] Group 2: Tilray Brands - Tilray Brands also has a comprehensive portfolio of cannabis products and operates in several countries, including the U.S., Germany, and Portugal, and has diversified into craft brewing and hemp-based products [5] - In Q2 of its 2026 fiscal year, Tilray reported net revenue of $217.5 million, a 3% year-over-year increase, while its net loss improved to $0.41 from $0.99 in the previous year [6] - Tilray is well-positioned to take advantage of emerging opportunities in the U.S. cannabis market, which could lead to significant share price increases if successful [6]

Canadian Cannabis Companies Are Dominating Global Deals - Moby THE GIST The cannabis industry is emerging from the doldrums with a splashy deal: Canadian firm Organigram (OGI) will pay up to €250 million (about $295 million) for German medical cannabis producer Sanity Group. That breaks down to an up-front consideration of €113.4 million plus a maximum earn-out of up to €113.8 million tied to financial performance. WHAT HAPPENED The deal gives Organigram a footprint in the E.U. as more countries on the ...

Industry Overview - The U.S. cannabis sector is adjusting as February 2026 approaches, with a shift in focus towards sustainability and execution rather than rapid expansion [1] - Higher interest rates have prompted companies to reassess spending habits, making balance sheet strength increasingly important [1] - Revenue quality is prioritized over headline growth figures, with companies generating consistent sales standing out [1] Market Dynamics - State-level legalization continues to expand, with several markets maturing into stable revenue generators, providing predictable consumer demand [2] - Medical and adult-use programs are key growth drivers, while federal reform discussions linger as a potential catalyst for the sector [2] - Uncertainty regarding federal reform limits institutional participation in the cannabis market [2] Investor Behavior - Retail investors play a critical role in cannabis trading volume, with February marking renewed interest after year-end repositioning [3] - Tax-loss selling pressure typically fades by February, allowing fundamentally sound stocks to attract attention [3] - Dispensary count and geographic exposure are key evaluation metrics, with diversified operators reducing market-specific risk [3] Financial Discipline - Financial discipline is essential for long-term survival, with companies generating real revenue gaining investor credibility [4] - Companies relying on speculation face increasing pressure, highlighting the importance of operational efficiency and cost management [4] Company Profiles Planet 13 Holdings Inc. (PLNH) - Operates as a vertically integrated cannabis retailer, known for its large Las Vegas dispensary that attracts both tourists and locals [5][6] - Emphasizes experiential retail, blending entertainment and product selection to differentiate from traditional dispensaries [5] - Operates over ten dispensaries nationwide and produces its own cannabis products, targeting premium consumers [6][9] - Revenue has fluctuated due to pricing pressure, but the company continues to generate meaningful quarterly sales [9] - Management focuses on reducing operating expenses and improving margins while monitoring same-store sales trends [10][11] FLUENT Corp. (CNTMF) - Operates as a regional cannabis company with a significant presence in Florida, one of the largest medical cannabis markets [11][12] - Emphasizes controlled expansion and brand consistency, operating over thirty dispensaries nationwide [12][14] - Generates over $100 million in annual revenue, with modest growth affected by pricing pressure [14] - Management focuses on operational efficiency and improving liquidity, with moderate debt levels compared to larger peers [15] Verano Holdings Corp. (VRNOF) - One of the largest cannabis operators in the U.S., with a strong presence in states like Illinois and Florida [16][17] - Operates over 150 dispensaries and owns several cultivation facilities, supporting supply chain control [17][19] - Generates substantial revenue but continues to report net losses due to pricing pressure and elevated operating costs [19] - Management is focused on cost optimization and selective retail expansion, with future profitability dependent on margin recovery [20]

Thailand once bet big on cannabis. Now, with public opinion turning and an election ahead, that gamble may backfire.@patpichatan explains: https://t.co/3t0kraAonM https://t.co/RjwhKev3M2 ...

Core Insights - WM Technology, Inc. announced the appointment of Harry DeMott and Brent Cox to its Board of Directors, effective February 1, 2026, while Susan Echard will transition to a full-time Chief Financial Officer role on January 30, 2026 [1][2] Group 1: Board Appointments - Harry DeMott brings extensive experience in the cannabis and technology sectors, having co-founded Raptor Ventures and Outsider Labs, and previously served as CEO of Proper [2][3] - Brent Cox is a seasoned investment professional with a focus on growth and regulated businesses, currently serving as Founder and Managing Principal of Subtext Holdings [3] Group 2: Company Overview - WM Technology operates Weedmaps, a leading cannabis marketplace, and offers eCommerce and compliance software solutions for cannabis businesses [4][5] - The Weedmaps marketplace has become a premier destination for cannabis consumers, providing access to products, daily deals, and educational resources [5] Group 3: Company Mission - The company advocates for full U.S. legalization, social equity within the industry, and ongoing education about cannabis through partnerships and expert collaborations [6]

Core Thesis - Cronos Group Inc. is experiencing a bullish sentiment driven by renewed interest from the White House in rescheduling marijuana, leading to significant stock price increases and a positive outlook for the company's long-term positioning [3][4]. Company Overview - Cronos Group Inc. is a cannabinoid company involved in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally [3]. Regulatory Changes - Plans to reclassify marijuana as a Schedule III substance could significantly reduce regulatory and tax burdens for the U.S. cannabis industry, which is expected to benefit Cronos Group [4][5]. - A Schedule III classification would allow cannabis operators to deduct normal operating expenses and access standard tax credits, enhancing cash flow and profitability potential for Cronos Group [5]. Strategic Positioning - Cronos Group is strategically backed by Altria Group and has existing U.S. exposure through PharmaCann, which operates 51 dispensaries across multiple states, positioning the company favorably ahead of potential federal legalization [5][6]. - Management views Canada as a pilot market, with the U.S. and Europe representing significant long-term growth opportunities as regulations evolve [6]. Market Performance - Since the initial bullish thesis, Cronos Group's stock has increased by approximately 67%, outperforming peers and cannabis ETFs, as investors anticipate improved fundamentals and market access [4]. Future Outlook - The potential rescheduling of marijuana could accelerate medical research and FDA-approved cannabis applications, further supporting the investment case for Cronos Group [7]. - The combination of improving regulatory momentum, tax normalization, strategic U.S. optionality, and disciplined long-term planning reinforces the attractiveness of Cronos Group as a long-term investment [8].

Core Viewpoint - Canopy Growth has experienced a significant decline in stock value, losing over 99% and currently trading around $1, indicating that it may not be an attractive investment despite its low price [1] Financial Performance - Canopy Growth's revenue has been inconsistent, with a slight increase in net revenue of 6% year-over-year to CA$66.7 million ($49.3 million) in Q2 of fiscal year 2026 [3] - The company's net loss per share improved to CA$0.01 ($0.0074) compared to a loss of CA$1.48 ($1.09) in the same period last year [3] Industry Challenges - The cannabis industry faces structural problems, including significant regulatory oversight, intense competition, and illegal sales channels that undermine legal businesses [4] - The recent reclassification of cannabis from Schedule I to Schedule III in the U.S. may provide some benefits, such as easier access to banking and tax deductions, but it does not address Canopy Growth's specific challenges, especially given its struggles in the Canadian market since legalization in 2018 [5]